Thomopoulos C, et al. - Using data from relevant randomized, controlled trials (RCTs) as well as from previous overviews, researchers determined the extent of different outcome reductions by glucose-lowering in patients with diabetes, and the proportionality of outcome reductions to glycated hemoglobin reductions. They also investigated if glucose-lowering outcome effects can be modified by ongoing blood pressure (BP) and LDL cholesterol difference in RCTs. In this analysis, they did not include RCTs of acute care, glucose intolerance, type 1 diabetes, multiple interventions applied, and glucose-lowering by lifestyle or other interventions. Eligible RCTs were 25 in total (n = 174,235; follow-up 3.5 years). The resulted ongoing systolic BP/diastolic BP difference was −1.4/−0.4 mmHg. Accurate estimates of benefits for coronary heart disease (CHD) and major cardiovascular events after taking the resulting ongoing BP difference into account were generated via meta-analyses of all glucose-lowering RCTs including patients with diabetes. Findings revealed no benefit or harm on mortality, heart failure, and stroke, while glucose-lowering was followed by a rise in discontinuations associated with adverse events due to treatment. Findings revealed a proportional association of the extent of glucose-lowering with changes of CHD and stroke composite, and treatment-associated discontinuations.